|
Gene: TLE2 |
Gene summary for TLE2 |
Gene summary. |
Gene information | Species | Human | Gene symbol | TLE2 | Gene ID | 7089 |
Gene name | TLE family member 2, transcriptional corepressor | |
Gene Alias | ESG | |
Cytomap | 19p13.3 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q04725 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
7089 | TLE2 | male-WTA | Human | Thyroid | PTC | 2.43e-32 | 2.71e-01 | 0.1037 |
7089 | TLE2 | PTC01 | Human | Thyroid | PTC | 3.95e-15 | 2.14e-01 | 0.1899 |
7089 | TLE2 | PTC03 | Human | Thyroid | PTC | 4.75e-03 | 1.59e-01 | 0.1784 |
7089 | TLE2 | PTC04 | Human | Thyroid | PTC | 7.83e-15 | 2.82e-01 | 0.1927 |
7089 | TLE2 | PTC05 | Human | Thyroid | PTC | 9.16e-26 | 7.05e-01 | 0.2065 |
7089 | TLE2 | PTC06 | Human | Thyroid | PTC | 8.67e-27 | 6.90e-01 | 0.2057 |
7089 | TLE2 | PTC07 | Human | Thyroid | PTC | 2.29e-27 | 5.08e-01 | 0.2044 |
7089 | TLE2 | ATC13 | Human | Thyroid | ATC | 1.76e-17 | 2.69e-01 | 0.34 |
7089 | TLE2 | ATC5 | Human | Thyroid | ATC | 3.19e-20 | 2.98e-01 | 0.34 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Thyroid | ATC: Anaplastic thyroid cancer | |
HT: Hashimoto's thyroiditis | ||
PTC: Papillary thyroid cancer |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0016055110 | Thyroid | PTC | Wnt signaling pathway | 217/5968 | 444/18723 | 3.71e-14 | 2.30e-12 | 217 |
GO:0198738110 | Thyroid | PTC | cell-cell signaling by wnt | 217/5968 | 446/18723 | 6.68e-14 | 3.73e-12 | 217 |
GO:0030111110 | Thyroid | PTC | regulation of Wnt signaling pathway | 163/5968 | 328/18723 | 1.05e-11 | 4.29e-10 | 163 |
GO:0060828110 | Thyroid | PTC | regulation of canonical Wnt signaling pathway | 123/5968 | 253/18723 | 1.83e-08 | 4.26e-07 | 123 |
GO:0060070110 | Thyroid | PTC | canonical Wnt signaling pathway | 141/5968 | 303/18723 | 5.71e-08 | 1.21e-06 | 141 |
GO:003017810 | Thyroid | PTC | negative regulation of Wnt signaling pathway | 74/5968 | 170/18723 | 8.99e-04 | 5.48e-03 | 74 |
GO:00900907 | Thyroid | PTC | negative regulation of canonical Wnt signaling pathway | 59/5968 | 137/18723 | 3.76e-03 | 1.80e-02 | 59 |
GO:001605525 | Thyroid | ATC | Wnt signaling pathway | 234/6293 | 444/18723 | 4.64e-17 | 4.31e-15 | 234 |
GO:019873825 | Thyroid | ATC | cell-cell signaling by wnt | 234/6293 | 446/18723 | 9.26e-17 | 8.25e-15 | 234 |
GO:003011125 | Thyroid | ATC | regulation of Wnt signaling pathway | 177/6293 | 328/18723 | 1.83e-14 | 1.05e-12 | 177 |
GO:006082825 | Thyroid | ATC | regulation of canonical Wnt signaling pathway | 134/6293 | 253/18723 | 1.49e-10 | 4.56e-09 | 134 |
GO:006007025 | Thyroid | ATC | canonical Wnt signaling pathway | 154/6293 | 303/18723 | 3.68e-10 | 1.02e-08 | 154 |
GO:003017815 | Thyroid | ATC | negative regulation of Wnt signaling pathway | 85/6293 | 170/18723 | 6.94e-06 | 7.16e-05 | 85 |
GO:009009014 | Thyroid | ATC | negative regulation of canonical Wnt signaling pathway | 66/6293 | 137/18723 | 2.82e-04 | 1.80e-03 | 66 |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TLE2 | SNV | Missense_Mutation | rs865946930 | c.1223N>T | p.Ser408Phe | p.S408F | protein_coding | tolerated(0.13) | possibly_damaging(0.684) | TCGA-VS-A8Q8-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD | |
TLE2 | SNV | Missense_Mutation | rs752674140 | c.1004N>T | p.Thr335Met | p.T335M | protein_coding | tolerated(0.35) | probably_damaging(0.987) | TCGA-A6-6653-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
TLE2 | SNV | Missense_Mutation | novel | c.1907N>T | p.Ser636Phe | p.S636F | protein_coding | deleterious(0) | probably_damaging(0.988) | TCGA-AA-3852-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
TLE2 | SNV | Missense_Mutation | novel | c.1885N>A | p.Asp629Asn | p.D629N | protein_coding | deleterious(0.04) | benign(0.071) | TCGA-AD-6964-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | folfox | PD | |
TLE2 | SNV | Missense_Mutation | novel | c.1657G>A | p.Ala553Thr | p.A553T | protein_coding | deleterious(0) | probably_damaging(0.92) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR | |
TLE2 | SNV | Missense_Mutation | c.638N>A | p.Gly213Asp | p.G213D | protein_coding | tolerated(0.37) | benign(0.046) | TCGA-CK-5916-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | ||
TLE2 | SNV | Missense_Mutation | c.1463N>G | p.Gln488Arg | p.Q488R | protein_coding | tolerated(0.07) | possibly_damaging(0.659) | TCGA-G4-6302-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
TLE2 | SNV | Missense_Mutation | c.950N>A | p.Gly317Glu | p.G317E | protein_coding | deleterious(0) | probably_damaging(0.982) | TCGA-G4-6304-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Chemotherapy | fluorouracil | PD | ||
TLE2 | SNV | Missense_Mutation | rs764714978 | c.1867N>T | p.Arg623Cys | p.R623C | protein_coding | deleterious(0.02) | benign(0.144) | TCGA-NH-A6GB-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | oxaliplatin | SD | |
TLE2 | SNV | Missense_Mutation | novel | c.563C>T | p.Ala188Val | p.A188V | protein_coding | tolerated(0.38) | benign(0.005) | TCGA-AG-3896-01 | Colorectum | rectum adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |